Grossfeld GD, et al. 2001b. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy–part I: deﬁnition, detection, prevalence, and etiology. Urology, 57:599–603. Guay DR. 2003. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet, 42:1243–85. Haab F, et al. 2004. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol, 45:420–9; discussion 429. Kay G, et al. 2006. Differential effects of the antimuscarinic agents dari- fenacin and oxybutynin ER on memory in older subjects. Eur Urol, 50:317–26. Lam S, Hilas O. 2007. Pharmacologic management of overactive bladder. Clin Interv Aging, 2:337–45. Malone DC, Okano GJ. 1999. Treatment of urge incontinence in Veterans Affairs medical centers. Clin Ther, 21:867–77. Michel MC, et al. 2002. Does gender or age affect the efﬁcacy and safety of tolterodine? J Urol, 168:1027–31. Nabi G, et al. 2006. Anticholinergic drugs versus placebo for overac- tive bladder syndrome in adults. Cochrane Database Syst Rev, (4): CD003781. Oehlke KJ. 2005. New treatment options for overactive bladder. S D J Med, 58: 225–6. Pontari MA, et al. 2004. The M2 muscarinic receptor mediates in vitro blad- der contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol, 286:R874–80. Reeves P, et al. 2006. The current and future burden and cost of overactive bladder in ﬁve European countries. Eur Urol, 50:1050–7. Darifenacin for overactive bladder Schaefer W. 2007. Comparison of the efﬁcacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol, 14:670; author reply 670–1. Staskin D, et al. 2007. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multi- center phase III trial. J Urol, 178:978–83; discussion 983–4. Stevens LA, et al. 2007. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol, 52:531–8. Thom DH, et al. 1997. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing, 26:367–74. Wagg A, et al. 2006. Efﬁcacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother, 4:14–24. Wefer J, et al. 2001. Tolterodine: an overview. World J Urol, 19:312–8. Wein AJ, Rovner ES. 2002. Deﬁnition and epidemiology of overactive bladder. Urology, 60(5 Suppl 1):7–12; discussion 12. Wein AJ. 1998. Pharmacologic options for the overactive bladder. Urology, 51(2A Suppl):43–7. Yamanishi T, et al. 2001. Which muscarinic receptor is important in the bladder? World J Urol, 19:299–306. Zinner N, et al. 2004. Trospium chloride improves overactive bladder symp- toms: a multicenter phase III trial. J Urol, 171:2311–5, quiz 2435. Clinical Interventions in Aging 2008:3(3) 509